Amgen Inc.’s Stock Price Plummets to $312.50, Marking a 5% Drop in Value

Amgen Inc. (AMGN)

312.50 USD -16.45 (-5.00%) Volume: 4.53M

Amgen Inc.’s stock price is currently at 312.50 USD, experiencing a 5.00% drop in this trading session with a trading volume of 4.53M. Despite today’s downturn, the biopharmaceutical giant’s stock maintains a positive year-to-date (YTD) increase of 8.50%, highlighting its resilience in the market and potential for growth in the biotech sector.

Latest developments on Amgen Inc.

Amgen Inc. (AMGN) reported a 45.9% decline in net income to $746 million in Q2 2024, causing its stock to fall despite beating revenue estimates and raising its full-year outlook. The company’s quarterly sales surpassed estimates, bolstered by the success of its weight-loss drug MariTide and the integration of Horizon. Analysts remain optimistic about Amgen’s long-term growth prospects, despite near-term challenges. The stock price movements today were also influenced by a patent loss to treat dialysis patients and a drug monopoly suit by a Maryland insurance provider. Overall, Amgen’s mixed Q2 results highlighted the potential of its obesity drug and upcoming clinical readouts, positioning the company for continued growth in the biopharmaceutical market.

Amgen Inc. on Smartkarma

Analysts at Baptista Research have been closely following Amgen Inc‘s recent performance and strategic moves. In their research report titled “Amgen Inc.: Will The Increased Spending on Research and Development (R&D) Pay Off? – Major Drivers,” they highlighted the company’s strong growth in Q1 of 2024, with total revenue increasing by 22% YoY. The report mentions the positive impact of strong volume growth and robust product sales from brands like Repatha, TEZSPIRE, EVENITY, Prolia, and BLINCYTO. Additionally, Amgen’s pipeline progress and development were discussed in another report by Baptista Research titled “Amgen Inc: An Analysis Of The Pipeline Progress and Development! – Major Drivers.” The analysts highlighted strategic moves, such as the acquisition of Horizon Therapeutics, and the record annual sales of 18 medicines, indicating a positive outlook for the company.

A look at Amgen Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Amgen Inc. has received a mixed outlook based on the Smartkarma Smart Scores. While the company scores high in Dividend and Momentum, indicating a strong performance in these areas, it falls short in Value and Resilience. With a moderate score in Growth, Amgen Inc. may need to focus on improving its value and resilience factors to ensure long-term success.

Despite facing some challenges in certain areas, Amgen Inc. remains a key player in the biotechnology industry. With a focus on developing innovative medicines for serious illnesses, the company’s emphasis on human therapeutics and cutting-edge research in cellular and molecular biology sets it apart in the market. By leveraging its strengths in Dividend and Momentum, Amgen Inc. can continue to make a significant impact in the healthcare sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma